These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33760230)

  • 1. Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology-enabled nomogram.
    Hartmann J; Ragusa MJ; Burchardt ER; Manukyan Z; Popovsky MA; Leitman SF
    Transfusion; 2021 Jun; 61(6):1789-1798. PubMed ID: 33760230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale real-world data analysis of source plasma collections using a novel technology-enabled nomogram.
    Hellman E; Manukyan Z; Mkhitaryan K; Heidarsdottir K; Ragusa MJ; Hartmann J
    Transfusion; 2023 Dec; 63(12):2256-2264. PubMed ID: 37839089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmavigilance-Adverse events among US Source plasma donors.
    Schreiber GB; Becker M; Fransen M; Hershman J; Lenart J; Song G; Simon T
    Transfusion; 2021 Oct; 61(10):2941-2957. PubMed ID: 34390267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study.
    Cho JH; Rajbhandary S; van Buren NL; Fung MK; Al-Ghafry M; Fridey JL; Dy BA; Ziman A; Schreiber GB; Gammon RR; Reik R; Stubbs JR; van Buskirk CM; Kamel H; Townsend MJ; Zeller MP; Gottschall JL
    Transfusion; 2021 Sep; 61(9):2668-2676. PubMed ID: 34227689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 related callback in blood donors; Outcomes in blood donors and patients.
    Balagholi S; Maghsudlu M; Amini-Kafiabad S; Nazemi AM; Sotoudeh Anvari M
    Transfus Apher Sci; 2021 Aug; 60(4):103129. PubMed ID: 33879420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pandemic blood donor demographics - Do changes impact blood safety?
    Vassallo RR; Bravo MD; Kamel H
    Transfusion; 2021 May; 61(5):1389-1393. PubMed ID: 33554333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New blood donors in times of crisis: Increased donation willingness, particularly among people at high risk for attracting SARS-CoV-2.
    Spekman MLC; Ramondt S; Quee FA; Prinsze FJ; Huis In 't Veld EMJ; van den Hurk K; Merz EM
    Transfusion; 2021 Jun; 61(6):1822-1829. PubMed ID: 33634876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The INTERVAL trial to determine whether intervals between blood donations can be safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled trial.
    Moore C; Sambrook J; Walker M; Tolkien Z; Kaptoge S; Allen D; Mehenny S; Mant J; Di Angelantonio E; Thompson SG; Ouwehand W; Roberts DJ; Danesh J
    Trials; 2014 Sep; 15():363. PubMed ID: 25230735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat donation and deferral rates in US source plasma donors: Exploratory analysis from the IMPACT trial.
    Hartmann J; Ragusa MJ; Burchardt ER; Manukyan Z; Popovsky MA; Leitman SF
    Transfusion; 2021 Oct; 61(10):2849-2854. PubMed ID: 34309028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor vigilance data of a blood transfusion service: A multicenter analysis.
    Burkhardt T; Dimanski B; Karl R; Sievert U; Karl A; Hübler C; Tonn T; Sopvinik I; Ertl H; Moog R
    Transfus Apher Sci; 2015 Oct; 53(2):180-4. PubMed ID: 26074050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor safety in an individualized plasmapheresis program - Results of an interim analysis.
    Taborski U; Laitinen T
    Transfus Apher Sci; 2022 Oct; 61(5):103446. PubMed ID: 35461780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective trial assessing the safety and efficacy of collecting up to 840 mL of plasma in conjunction with saline infusion during plasmapheresis.
    Buzza M; Marks DC; Capper H; Cassin E; Badcock CA; Reid S; Kwok M; Yang H; Lee J; Corrigan C; Hartkopf-Theis T; Keller A
    Transfusion; 2012 Aug; 52(8):1806-13. PubMed ID: 22348664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eighteen years experience of granulocyte donations-acceptable donor safety?
    Axdorph Nygell U; Sollén-Nilsson A; Lundahl J
    J Clin Apher; 2015 Oct; 30(5):265-72. PubMed ID: 25546372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of donation frequency on donor health in blood donors donating plasma by plasmapheresis: study protocol for a randomized controlled trial.
    Haugen M; Magnussen K; Aarsland TE; Nissen-Meyer LSH; Strand TA
    Trials; 2024 Mar; 25(1):175. PubMed ID: 38468338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of COVID-19 on blood safety and availability in the Islamic Republic of Iran.
    Divkolaye N; Arabkhazaeli A; Hajibeigi B; Eshghi P
    East Mediterr Health J; 2022 Nov; 28(11):823-828. PubMed ID: 36515446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Source Plasma Donation: The Experience of the Iranian Blood Transfusion Organization.
    Mohammadi S; Aghabozorg F; Balagholi S; Ferdowsi S; Sharifi S; Eshghi P
    Int J Hematol Oncol Stem Cell Res; 2022 Jul; 16(3):151-156. PubMed ID: 36694705
    [No Abstract]   [Full Text] [Related]  

  • 18. Detection of hepatitis C virus (HCV) core-specific antibody suggests occult HCV infection among blood donors.
    Quiroga JA; Avellón A; Bartolomé J; Andréu M; Flores E; González MI; González R; Pérez S; Richart LA; Castillo I; Alcover J; Palacios R; Carreño V; Echevarría JM
    Transfusion; 2016 Jul; 56(7):1883-90. PubMed ID: 27185049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
    Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
    Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Offering new and returned donors the option to give plasma: implications for donor retention and donor adverse events.
    Thijsen A; Davison TE; Speedy J; Hoad V; Masser B
    Vox Sang; 2021 Mar; 116(3):273-280. PubMed ID: 32702163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.